Literature DB >> 12496959

Therapeutic dendritic-cell vaccine for simian AIDS.

Wei Lu1, Xiaoxian Wu, Yaozeng Lu, Weizhong Guo, Jean-Marie Andrieu.   

Abstract

An effective immune response against human immunodeficiency virus or simian immunodeficiency virus (SIV) is critical in achieving control of viral replication. Here, we show in SIV-infected rhesus monkeys that an effective and durable SIV-specific cellular and humoral immunity is elicited by a vaccination with chemically inactivated SIV-pulsed dendritic cells. After three immunizations made at two-week intervals, the animals exhibited a 50-fold decrease of SIV DNA and a 1,000-fold decrease of SIV RNA in peripheral blood. Such reduced viral load levels were maintained over the remaining 34 weeks of the study. Molecular and cellular analyses of axillary and inguinal node lymphocytes of vaccinated monkeys revealed a correlation between decreased SIV DNA and RNA levels and increased SIV-specific T-cell responses. Neutralizing antibody responses were augmented and remained elevated. Inactivated whole virus-pulsed dendritic cell vaccines are promising means to control diseases caused by immuno- deficiency viruses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12496959     DOI: 10.1038/nm806

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  76 in total

Review 1.  Memory CD8 T-cell differentiation during viral infection.

Authors:  E John Wherry; Rafi Ahmed
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

2.  DNA/Ad5 vaccination with SIV epitopes induced epitope-specific CD4⁺ T cells, but few subdominant epitope-specific CD8⁺ T cells.

Authors:  Lara Vojnov; Alexander T Bean; Eric J Peterson; Maria J Chiuchiolo; Jonah B Sacha; Ferencz S Denes; Matyas Sandor; Deborah H Fuller; James T Fuller; Christopher L Parks; Adrian B McDermott; Nancy A Wilson; David I Watkins
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

3.  Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity.

Authors:  Celestine N Wanjalla; Elizabeth J Faul; Emily A Gomme; Matthias J Schnell
Journal:  Vaccine       Date:  2010-08-20       Impact factor: 3.641

4.  Bone marrow plasmacytoid dendritic cells can differentiate into myeloid dendritic cells upon virus infection.

Authors:  Elina I Zuniga; Dorian B McGavern; Jose L Pruneda-Paz; Chao Teng; Michael B A Oldstone
Journal:  Nat Immunol       Date:  2004-11-07       Impact factor: 25.606

Review 5.  HIV-1 and the hijacking of dendritic cells: a tug of war.

Authors:  Marie Larsson
Journal:  Springer Semin Immunopathol       Date:  2005-01

6.  Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef.

Authors:  Daniel G Kavanagh; Daniel E Kaufmann; Sherzana Sunderji; Nicole Frahm; Sylvie Le Gall; David Boczkowski; Eric S Rosenberg; David R Stone; Mary N Johnston; Bradford S Wagner; Mohammad T Zaman; Christian Brander; Eli Gilboa; Bruce D Walker; Nina Bhardwaj
Journal:  Blood       Date:  2005-10-25       Impact factor: 22.113

7.  Generation of feline dendritic cells derived from peripheral blood monocytes for in vivo use.

Authors:  Giulia Freer; Donatella Matteucci; Paola Mazzetti; Leonia Bozzacco; Mauro Bendinelli
Journal:  Clin Diagn Lab Immunol       Date:  2005-10

8.  Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques.

Authors:  Koen K A Van Rompay; Raman P Singh; Walid Heneine; Jeffrey A Johnson; David C Montefiori; Norbert Bischofberger; Marta L Marthas
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

Review 9.  DC-based cancer vaccines.

Authors:  Eli Gilboa
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

10.  Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239.

Authors:  Panagiotis Vagenas; Vennansha G Williams; Michael Piatak; Julian W Bess; Jeffrey D Lifson; James L Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.